Effect of anti-inflammatory activity of ranolazine in rat model of inflammation

R. Naveena¹, Nayana K. Hashilkar¹, Reshma Davangeri² & Suneel I. Majagi¹

Departments of ¹Pharmacology & ²Pathology, Jawaharlal Nehru Medical College, Belagavi, India

Received September 14, 2016

Background & objectives: Inflammatory processes are a recognized feature of atherosclerotic lesions. Ranolazine inhibits the inflammatory markers such as C-reactive protein, interleukins-1 and -6 and tumour necrosis factor-alpha. The present study was planned to evaluate the effect of anti-inflammatory activity of ranolazine in acute and sub-acute models of inflammation in rats and compare the same with that of control (gum acacia 1%) and aspirin (standard anti-inflammatory drug).

Methods: Adult male Wistar rats (150-180 g) were used for the study. They were divided into three groups (n=6). One per cent gum acacia (control), aspirin (200 mg/kg body weight) and ranolazine (180 mg/kg body weight) were given orally. Acute inflammation was induced by injecting carrageenan in the left hind paw. Paw oedema volume and percentage inhibition were measured. Subacute inflammation was induced by implanting foreign bodies subcutaneously. Percentage inhibition of granuloma dry weight and haematoxylin and eosin stained sections of granulation tissue were studied.

Results: In acute and subacute model study, ranolazine significantly (P<0.01) decreased the paw oedema volume and granuloma dry weight as compared to control and it was comparable to that of aspirin and histopathological sections showed a decrease in granulation tissue formation as compared to control.

Interpretation & conclusions: Ranolazine demonstrated significant anti-inflammatory activity in acute and subacute models of inflammation and needs further evaluation for its use in reducing atherosclerosis.

Key words Acute model - aspirin - atherosclerosis inflammation - ranolazine - subacute model

Inflammation is involved in the pathogenesis of atherosclerosis which is one of the major causes of coronary artery disease (CAD)¹. The inflammatory response involved in acute coronary events could be related with early and late post-ACS (acute coronary syndrome) adverse cardiac events²,³. Inflammation is also involved in the process of post-myocardial infarction (MI) healing process. The inflammation may have deleterious effects on myocardial cells, especially in case of an exuberant inflammatory response. Ischaemic myocardium produces certain important cytokines such as interferon gamma, tumour necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1). These cytokines, in turn, stimulate the production of IL-6 which triggers the inflammatory response and the platelet aggregation⁴. Inflammation directly interferes with the myocardial contractility, the vascular endothelial function and recruitment of other
inflammatory mediators such as C-reactive protein (CRP). This suggests that CRP and other inflammatory markers can be considered as direct inflammatory promoters with pro-atherogenic and pro-thrombotic properties. Further, it may be assumed that drugs which decrease CRP and other inflammatory mediators have additional benefits in CAD patients. It has been shown that metabolic modulator, an anti-anginal drug, ranolazine improves endothelial function by altering the inflammatory mediators. Ranolazine has also been shown to decrease inflammatory mediators such as IL-1 and TNF-α and increase anti-inflammatory peroxisome proliferator-activated receptor gamma.

The present study was undertaken to evaluate the effect of oral ranolazine on acute and subacute models of inflammation in male Wistar rats and compare these effects with that of control (1% gum acacia) and standard anti-inflammatory drug, aspirin.

**Material & Methods**

This experimental study was conducted in the department of Pharmacology, Jawaharlal Nehru Medical College (JNMC), Belagavi, Karnataka, India. Adult male Wistar rats (weighing between 150 and 180 g body weight) were obtained from the central animal house of JNMC. Animals were housed under standard laboratory conditions and acclimatized to 12 h light/dark cycle for 10 days prior to the day of experimentation. Animals had free access to food (standard rat chow pellet) and water ad libitum. The study was approved by the institutional animal ethics committee.

Male Wistar rats were randomly divided into control (gum acacia), standard (aspirin) and treatment (ranolazine) groups (n=6 in each). The drugs used were one per cent gum acacia orally, aspirin (200 mg/kg body weight of rat equivalent to 2222 mg of clinical dose orally) and ranolazine (180 mg/kg body weight of rat equivalent to 2000 mg of clinical dose orally).

**Acute inflammation by carrageenan-induced rat paw oedema:** Acute inflammation was induced by injecting 0.05 ml of one per cent carrageenan in sub plantar region of the left hind paw. A mark was made on the leg at the malleolus to facilitate uniform dipping at subsequent readings. The paw volume was measured with the help of plethysmograph (Instrumental and Chemical Private Limited, Ambala) by mercury displacement method using plethysmograph at zero hour (immediately after injecting carrageenan). The same procedure was repeated at 0.5, 1, 3, 4 and 5 h. The difference between zero hour and subsequent reading was taken as actual oedema volume. The percentage inhibition of oedema in the various treated groups was calculated by using the following formula:

\[
\text{Percentage inhibition of oedema} = 1 - \frac{\text{mean increase in paw volume in treated group}}{\text{mean increase in paw volume in control group}} \times 100
\]

**Subacute inflammation by foreign body-induced granuloma method:** Subacute inflammation was induced in all the groups after a washout period of 48 h. In overnight starved (with water ad libitum) rats, after clipping the hair in axilla and groin, two sterile cotton pellets weighing 10 mg and two sterile grass piths (25 mm×2 mm) were implanted subcutaneously, through a small incision, under light thiopentone anaesthesia. Wounds were sutured, and animals were caged individually after recovery from anaesthesia. Aseptic precautions were taken throughout the procedure. The treatment was started after implantation and was repeated every 24 h, regularly for 10 days. On the 11th day, the rats were sacrificed with an overdose of anaesthesia to remove cotton pellets and grass piths. The pellets, free from extraneous tissue were dried overnight at 60°C to note their dry weight. Net granuloma weight was calculated by subtracting initial weights of the cotton pellet (10 mg) from the weights noted. Mean granuloma dry weight for various groups was calculated and expressed as mg/100 g of body weight. The percentage inhibition of granuloma dry weight was calculated using the formula:

\[
\text{Percentage inhibition granuloma dry weight} = 1 - \frac{\text{dry weight of granuloma in treated group}}{\text{dry weight of granuloma in control group}} \times 100
\]

The grass piths were preserved in 10 per cent formalin for haematoxylin and eosin (H&E) staining.

**Statistical analysis:** The results were analyzed using ANOVA followed by post hoc test of the Dunnet’s and Bonferonni test.

**Results**

In acute model of carrageenan-induced inflammation, the mean paw oedema volumes for control group at ½, 1, 3, 4 and 5 h intervals, were 1.15±0.03, 1.31±0.01, 1.24±0.02, 1.26±0.02 and 1.16±0.02 ml, respectively (Table). The mean paw
The anti-anginal drug, ranolazine has a cardioprotective action by blocking the sodium current
that facilitates calcium entry through the sodium-calcium exchanger. One of the major events involved in
angina, myocardial infarction (MI) and atherosclerosis is inflammation. Inflammation is also involved in
the restenosis processes in those patients who have...
undergone percutaneous coronary intervention (PCI)\textsuperscript{19}. The results of the present study revealed that ranolazine could be exhibiting multiple mechanisms in CAD, \textit{i.e.} anti-inflammatory in addition to their pharmacological actions. This drug may be useful in reducing the inflammation involved in atherosclerosis and also post-ischaemic complications such as reinfarction and infarct extension, and also in preventing cardiovascular events like restenosis after PCI.

The study had limitations. Chronic anti-inflammatory effect of ranolazine was not studied. This would have given some information on long term therapeutic benefit in CVD patients. The effect of the drug on the inflammatory mediators such as IL, TNF-alpha and CRP has also not been investigated.

In conclusion, this experimental study was conducted to know the effect of anti-anginal drugs ranolazine on inflammation in both acute (carrageenan-induced rat paw oedema) and subacute (foreign-body-induced granuloma) models of inflammation in male Wistar rats. Ranolazine showed significant inhibition of rat paw oedema in acute model and granuloma dry weight, in subacute models of inflammation when compared to control. The anti-inflammatory effect of ranolazine was comparable to aspirin in acute and subacute models of inflammation. Drugs that reduce inflammation may have added benefits in the treatment of cardiovascular disease and also will be useful in reducing the post ischaemic complications. The role of ranolazine as anti-inflammatory agent warrants further investigation and has to be confirmed by clinical trials.

**Financial support & sponsorship:** None.

**Conflicts of Interest:** None.

**References**

1. Paoletti R, Gotto AM Jr., Hajjar DP. Inflammation in atherosclerosis and implications for therapy. \textit{Circulation} 2004; 109 (Suppl 1) : III20-6.
2. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. \textit{Cardiovasc Res} 2002; 53 : 31-47.
3. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. \textit{J Cardiol} 2009; 53 : 317-33.
4. Kuralay F, Altekim E, Yazlar AS, Ovnural B, Goldeli O. Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine. \textit{Tohoku J Exp Med} 2006; 208 : 203-12.
5. Shrivastavaa AK, Singh HV, Raizadac A, Singh SK. C-reactive protein, inflammation and coronary heart disease. \textit{Egypt Heart J} 2015; 67 : 89-97.
6. Deshmukh SH, Patel SR, Pinassi E, Mindrescu C, Hermance EV, Infante MN, \textit{et al.} Ranolazine improves endothelial function in patients with stable coronary artery disease. \textit{Coron Artery Dis} 2009; 20 : 343-7.
7. Katzung BG. Vasodilators and treatment of angina pectoris. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and clinical pharmacology: 12th ed. New Delhi: McGraw Hill Publishers; 2009. p. 193-210.

8. Laurence DR, Bacharach AL. Evaluation of drug activities: Pharamacometrics, Vol. 2. New York and London: Academic Press Inc.; 1964.

9. Sweetman SC. Martindale the complete drug reference, 36th ed. London: Pharmaceutical Press; 2009. p. 1320, 1386, 1349, 1419.

10. Vogel GH. Drug discovery and evaluation, pharmacological assays, 3rd ed. New York: Springer-Verlag Berlin Heidelberg; 2008. p. 1094-113.

11. Turner RA. Screening methods in pharmacology. New York and London: Academic Press Inc.; 1965.

12. Gupta SK, editor. Drug screening methods (Preclinical evaluation of new drugs). 2nd ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2009.

13. Bagger JP, Bøtker HE, Thomassen A, Nielsen TT. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther 1997; 11: 479-84.

14. Amrani F, Guerra S, Aguirre-Rueda D, Mauricio MD, Marchio P, Vila JM, et al. Anti-inflammatory and antioxidant effects of ranolazine on primary cultured astrocytes. Crit Care 2014; 18 (Suppl 1): P447.

15. Arango Duque G, Descoteaux A. Macrophage cytokines: Involvement in immunity and infectious diseases. Front Immunol 2014; 5: 491.

16. Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD, et al. Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol 2008; 153 (Suppl 1): S241-6.

17. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006; 92 (Suppl 4): iv6-iv14.

18. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr., Lerman A, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.

19. Vlaar PJ, Sviilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): A 1-year follow-up study. Lancet 2008; 371: 1915-20.

For correspondence: Dr R. Naveena, Department of Pharmacology, St. John’s Medical College, Sarjapur Main Road, Koramangala, Bengaluru 560 034, Karnataka, India

e-mail: drnaveenar26@gmail.com